Authors

Latest:

Dr Hassan on the CHRYSALIS trial of Amivantamab in EGFR Exon 20–Mutated NSCLC

Khaled Hassan, MD, discusses key results from the phase 1 CHRYSALIS trial of the bispecific antibody amivantamab-vmjw in non–small cell lung cancer expressing EGFR exon 20 insertion mutations.

Khaled A. Tolba MD, MBBCh

Latest:

Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma

Khaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.

Kieron Dunleavy, MD

Latest:

Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.

Kilian Salerno, MD

Latest:

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Kim A. Reiss Binder, MD

Latest:

Dr. Reiss Binder on Initial Results of a Phase 1 Study of CT-0508 in HER2+ Solid Tumors

Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.

Kim Chi, MD

Latest:

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

Kim Farina, PhD

Latest:

Is Our Healthcare System Ready to Integrate Cancer Care?

In response to the billions of dollars wasted each year in the United States on fragmented, ineffective, and uncoordinated care, some healthcare reform efforts have focused on integrating the delivery of healthcare.

Kim-Hien T. Dao, DO, PhD, Oregon Health & Science University

Kim Kelly, RN, OCN

Latest:

Kim Kelly on Clinical Practice Guidelines for Mucositis

Kim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis

Kim N. Chi, MD

Latest:

Dr. Chi on the TITAN Trial Results in Metastatic Castration-Sensitive Prostate Cancer

Kim N. Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the results of the phase III TITAN trial, which evaluated apalutamide versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Kimberly Blackwell, MD, Duke Cancer Institute

Kimberly J. Van Zee, MD

Latest:

Dr. Van Zee on Nomograms for Patients With DCIS

Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Kimberly L. Blackwell, MD

Latest:

Dr. Blackwell on the Treatment of Young Women With Breast Cancer

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Kimberly L. Blackwell, MD, Duke

Kimberly L. Blackwell, MD, Duke Cancer Institute

Kimberly L. Blackwell, MD, Duke University Medical Center

Kimberly L. Blackwell, MD, Duke University School of Medicine

Kimberly L. Johung, MD, PhD

Latest:

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged nonâ€“small cell lung cancer and brain metastases.

Kimberly S. Corbin, MD

Latest:

Dr. Corbin on Patient Selection for Proton Therapy in Breast Cancer

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Kimberly Van Zee, MD

Latest:

Dr. Van Zee on Prevention of Invasive Recurrence in Breast Cancer

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.